Company news
XORTX Therapeutics, Inc. news in 2026
XORTX Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
October 8, 2026
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market Opportunity
September 18, 2026
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO(TM)
September 10, 2026
XORTX Re-Engages Investor Relations Program
September 8, 2026
XORTX Announces Termination and Postponement of Investor Relations Program
August 28, 2026
XORTX Announces Director Resignation
July 31, 2026
XORTX Appoints New Director
July 29, 2026
XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO
June 15, 2026
XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange
June 12, 2026
XORTX Announces Closing of US$5 Million Public Offering
May 19, 2026
E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering
May 18, 2026
XORTX Announces US$5 Million Public Offering
May 14, 2026
XORTX Meets Nasdaq Continued Listing Requirements
April 21, 2026
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
April 13, 2026
XORTX Confirms Effective Date of Share Consolidation
April 1, 2026
XORTX Announces Results of Annual and Special Meeting of Shareholders
March 26, 2026
XORTX Announces Change of Effective Date of Share Consolidation
March 26, 2026
XORTX Announces Share Consolidation
March 25, 2026
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting
March 24, 2026
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders
March 18, 2026
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote "For" the Share Consolidation
March 13, 2026
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders
March 5, 2026
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
February 4, 2026
Decks in 2026
- Investor Presentation (June 2026)
Investor deck · 20 slides · June 2026